CBFA

CBFA Therapeutics is a preclinical-stage biotechnology company dedicated to developing novel small molecule therapeutics for Core Binding Factor (CBF) leukemias, a distinct subset of Acute Myeloid Leukemia (AML). The company's primary approach involves the use of targeted inhibitors designed to disrupt the protein-protein interaction between RUNX1 and CBFβ, which is oncogenically activated in these cancers. By specifically targeting the molecular drivers of the disease, CBFA Therapeutics aims to provide more effective and less toxic treatment options compared to standard chemotherapy. The company's research is rooted in foundational discoveries made at the University of Massachusetts Medical School.